Shanghai Shenqi Pharmaceutical Investment Management Co Ltd
SSE:600613
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd
Income from Continuing Operations
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd
SSE:600613
|
Income from Continuing Operations
¥58.4m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-11%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Income from Continuing Operations
¥5.6B
|
CAGR 3-Years
29%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Income from Continuing Operations
¥8.1B
|
CAGR 3-Years
28%
|
CAGR 5-Years
5%
|
CAGR 10-Years
13%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Income from Continuing Operations
¥5.2B
|
CAGR 3-Years
22%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
7%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Income from Continuing Operations
¥6.8B
|
CAGR 3-Years
23%
|
CAGR 5-Years
14%
|
CAGR 10-Years
33%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Income from Continuing Operations
¥3.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
244%
|
CAGR 10-Years
N/A
|
|
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd
Glance View
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. engages in the research and development, manufacture, and sale of antitumor, cardiovascular, cold and cough, children medicine, and anti fungi drugs. The company is headquartered in Shanghai, Shanghai and currently employs 1,371 full-time employees. is a China-based company principally engaged in research and development, manufacture and sale of pharmaceuticals. The Company’s products are targeted for the treatment of influenza, cardio cerebrovascular diseases, rheumatoid bone diseases and in the areas of oncology, antifungal, antipyretic and gynaecology. The firm's main products include cantharidin sodium vitamin B6 injection, cantharidin sodium injection and other Chinese patent drug products. The firm distributes its products in domestic market.
See Also
What is Shanghai Shenqi Pharmaceutical Investment Management Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
58.4m
CNY
Based on the financial report for Sep 30, 2025, Shanghai Shenqi Pharmaceutical Investment Management Co Ltd's Income from Continuing Operations amounts to 58.4m CNY.
What is Shanghai Shenqi Pharmaceutical Investment Management Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-11%
Over the last year, the Income from Continuing Operations growth was 13%. The average annual Income from Continuing Operations growth rates for Shanghai Shenqi Pharmaceutical Investment Management Co Ltd have been -6% over the past three years , and -11% over the past ten years .
